More Bang for Your Buck. Leveraging Lab Developed Tests to Accelerate CDx Development

Time: 11:00 am
day: Day Two Morning


• NeoGenomics has extensive experience with Lab Developed Tests (LDTs) to support early phase CDx programs across multiple technologies and therapeutic classes
• Use of LDTs allows for faster development cycles and can significantly lower costs for early-phase CDx programs, but this approach presents risks for downstream commercialization
• Here we give an overview of best practices (including a case study) to ensure LDTs are fit for purpose for early phase studies and have an optimal yet practical pathway for partnering with an IVD manufacturer for final Phase 3 support, regulatory approval, and commercial launch